10–15% Body Weight Loss Best Seller

Semaglutide (Ozempic® / Wegovy®)

Semaglutide is the GLP-1 receptor agonist behind Ozempic® and Wegovy®. In the landmark STEP trials, men taking semaglutide alongside a structured lifestyle program lost an average of 14.9% of body weight over 68 weeks — a number previously achievable only with surgery.

How it works

The mechanism

Semaglutide binds GLP-1 receptors in the gut, pancreas and brain. It slows gastric emptying so meals stay satisfying for hours, suppresses central food-craving signals, and improves insulin response so blood sugar stops driving cravings. The cumulative effect is a comfortable, sustainable calorie deficit.

Who it's for

Best candidates

  • Men with BMI ≥27 with comorbidities, or BMI ≥30
  • Patients with food noise, late-night snacking, or repeated diet rebounds
  • Men who want a clinically proven, well-studied option

Protocol

Once-weekly subcutaneous injection. Start at 0.25 mg, titrate every 4 weeks: 0.5 → 1.0 → 1.7 → 2.4 mg. Most men reach effective doses by week 12–16.

Timeline

Appetite drops within days. Visible weight loss by week 4. Trial-level results (12–15%) typically reached by month 9–12.

What to expect

Side effects & considerations

Nausea, constipation, fatigue, occasional reflux. Mostly resolved by slowing titration and adjusting nutrition.

Frequently asked

Semaglutide (Ozempic® / Wegovy®) FAQs

Pairs well with

Related treatments

Take the first step

Feel like yourself again — book a free consult.

15 minutes. No pressure. A clear plan if you want one.